

Edgar Filing: BIOTRANSPLANT INC - Form SC 13D/A

BIOTRANSPLANT INC  
Form SC 13D/A  
January 13, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
SCHEDULE 13D  
-----

INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND 13D-2  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 3) \*

BIOTRANSPLANT INCORPORATED  
(NAME OF ISSUER)

COMMON STOCK, PAR VALUE \$.01 PER SHARE  
(TITLE OF CLASS OF SECURITIES)

09066Y 10 7  
(CUSIP NUMBER)

Hank Gracin, Esq.  
Lehman & Eilen LLP  
50 Charles Lindbergh Blvd., Suite 505  
Uniondale, New York 11553  
(516) 222-0888  
(NAME, ADDRESS, TELEPHONE NUMBER OF PERSON AUTHORIZED  
TO RECEIVE NOTICES AND COMMUNICATION)

December 22, 2003  
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the Acquisition which is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(f) or 240.13d(g), check the following box: / /

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss. 24013d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: BIOTRANSPLANT INC - Form SC 13D/A

CUSIP NO. 09066y 10 7

13D/A

Page 2 of 9 Pages

1. NAME OF REPORTING PERSON, I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:  
Little Wing, L.P., 13-3778596
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*:  
(a) / /  
(b) /X/
3. SEC USE ONLY
4. SOURCE OF FUNDS:
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E): / /
6. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
7. SOLE VOTING POWER: 0 shares
8. SHARED VOTING POWER: 0 shares
9. SOLE DISPOSITIVE POWER: 0 shares
10. SHARED DISPOSITIVE POWER: 0 shares
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 0 shares
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:\* / /
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 0 %
14. TYPE OF REPORTING PERSON\*: PN

CUSIP NO. 09066y 10 7

13D/A

Page 3 of 9 Pages

1. NAME OF REPORTING PERSON, I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:  
Tradewinds Fund Ltd.
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*:  
(a) / /  
(b) /X/
3. SEC USE ONLY
4. SOURCE OF FUNDS:
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E): / /

Edgar Filing: BIOTRANSPLANT INC - Form SC 13D/A

- 6. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
- 7. SOLE VOTING POWER: 0 shares
- 8. SHARED VOTING POWER: 0 shares
- 9. SOLE DISPOSITIVE POWER: 0 shares
- 10. SHARED DISPOSITIVE POWER: 0 shares
- 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 0 shares
- 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:\* / /
- 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 0%
- 14. TYPE OF REPORTING PERSON\*: CO

CUSIP NO. 09066y 10 7

13D/A

Page 4 of 9 Pages

- 1. NAME OF REPORTING PERSON, I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:  
Quilcap Corp., 13-3780878
- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*:  
(a) / /  
(b) /X/
- 3. SEC USE ONLY
- 4. SOURCE OF FUNDS:
- 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E): / /
- 6. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
- 7. SOLE VOTING POWER: 0 shares
- 8. SHARED VOTING POWER: 0 shares
- 9. SOLE DISPOSITIVE POWER: 0 shares
- 10. SHARED DISPOSITIVE POWER: 0 shares
- 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 0 shares
- 12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:\* / /

Edgar Filing: BIOTRANSPLANT INC - Form SC 13D/A

13. PERCENT OF CLASS REPRESENTED BY  
AMOUNT IN ROW (11): 0%
14. TYPE OF REPORTING PERSON\*: CO

CUSIP NO. 09066y 10 7 13D/A Page 5 of 9 Pages

1. NAME OF REPORTING PERSON, I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:  
Quilcap International Corp., 13-3868725
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*:  
(a) / /  
(b) /X/
3. SEC USE ONLY
4. SOURCE OF FUNDS:
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM  
2 (D) OR 2 (E): / /
6. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
7. SOLE VOTING POWER: 0 shares
8. SHARED VOTING POWER: 0 shares
9. SOLE DISPOSITIVE POWER: 0 shares
10. SHARED DISPOSITIVE POWER: 0 shares
11. AGGREGATE AMOUNT BENEFICIALLY  
OWNED BY EACH REPORTING PERSON: 0 shares
12. CHECK BOX IF THE AGGREGATE AMOUNT  
IN ROW (11) EXCLUDES CERTAIN SHARES:\* / /
13. PERCENT OF CLASS REPRESENTED BY  
AMOUNT IN ROW (11): 0%
14. TYPE OF REPORTING PERSON\*: CO

CUSIP NO. 09066y 10 7 13D/A Page 6 of 9 Pages

1. NAME OF REPORTING PERSON, I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:  
Parker Quillen 100-40-7015
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*:  
(a) / /  
(b) /X/

Edgar Filing: BIOTRANSPLANT INC - Form SC 13D/A

3. SEC USE ONLY
4. SOURCE OF FUNDS:
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E): / /
6. CITIZENSHIP OR PLACE OF ORGANIZATION: United States
7. SOLE VOTING POWER: 5,000 shares
8. SHARED VOTING POWER: 0 shares
9. SOLE DISPOSITIVE POWER: 5,000 shares
10. SHARED DISPOSITIVE POWER: 0 shares
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 5,000 shares
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:\* / /
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 0%
14. TYPE OF REPORTING PERSON\*: IN

CUSIP NO. 09066y 10 7

13D/A

Page 7 of 9 Pages

This Schedule 13D/A hereby amends the Schedules 13D, as originally filed with the United States Securities and Exchange Commission (the "Commission"), on August 2, 2002, as amended, relating to the beneficial ownership of the common stock, par value \$.01 per share (the "Common Stock") of BioTransplant Incorporated, a Delaware corporation (the "Issuer"), whose principal executive offices are located at 196 Boston Avenue, Suite 2800, Medford Massachusetts. Capitalized terms used in this Amendment No. 3 but not otherwise defined herein have the meanings given to such terms in the Schedule 13D.

Item 1. Security and Issuer

No amendment.

Item 2. Identity and Background

No amendment.

Item 3. Source and Amount of Funds or Other Consideration

No amendment.

Item 4. Purpose of Transaction

Edgar Filing: BIOTRANSPLANT INC - Form SC 13D/A

Item 4 is hereby amended in its entirety to provide as follows:

The Reporting Entities no longer intend to engage in actions designed to influence the Issuer's Board of Directors, or otherwise change or influence the control of the Issuer.

Item 5. Interest in Securities of the Issuer.  
-----

Item 5 is hereby amended in its entirety to provide as follows:

(a) The Reporting Entities ceased to be beneficial owners of more than 5% of the Common Stock as of December 22, 2003.

CUSIP NO. 09066y 10 7 13D/A Page 8 of 9 Pages

Specifically, as of December 23, 2003: (i) Little Wing, L.P. and Quilcap Corp. beneficially owned no shares of the Common Stock; and (ii) Tradewinds Fund Ltd. and Quilcap International Corp. beneficially owned no shares of the Common Stock. Parker Quillen beneficially owned 5,000 shares of the Common Stock as of December 9, 2003, constituting less than 1% of the Common Stock based on the Issuer's latest Form 10-Q filed with the Commission on November 19, 2002.

(b) Little Wing, L.P. has the power to vote and dispose of the Common Shares owned by it, which power may be exercised by Quilcap Corp., the general partner of Little Wing, L.P. Tradewinds Fund Ltd. has the power to vote and dispose of the Common Shares owned by it, which power may be exercised by Quilcap International Corp., the investment manager of Tradewinds Fund Ltd. Parker Quillen is the President of the Reporting Entities.

(c) Little Wing, L.P. sold 3,250,000 shares of the Common Stock on December 22, 2003 on the NASDAQ Stock Market, Inc. at \$.005 per share. Tradewinds Fund Ltd. sold 757,516 shares of the Common Stock on December 22, 2003 on the NASDAQ Stock Market, Inc. at \$.005 per share. Parker Quillen sold 200,000 shares of the Common Stock on December 9, 2003 on the NASDAQ Stock Market, Inc. at \$.01 per share.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

No amendment.

Item 7. Material to be Filed as Exhibits

No amendment

CUSIP NO. 09066y 10 7 13D/A Page 9 of 9 Pages

Signatures

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: January 13, 2004

Edgar Filing: BIOTRANSPLANT INC - Form SC 13D/A

LITTLE WING, L.P.

By: Quilcap Corp.

General Partner

By: /s/ Parker Quillen

-----

Parker Quillen, President

QUILCAP CORP.

By: /s/ Parker Quillen

-----

Parker Quillen, President

TRADEWINDS FUND LTD.

By: Quilcap International Corp.

By: : /s/ Parker Quillen

-----

Parker Quillen, President

QUILCAP INTERNATIONAL CORP.

By: /s/ Parker Quillen

-----

Parker Quillen, President

/s/ Parker Quillen

Parker Quillen